In August, Dr. Mikol presented unblinded data from the SAD cohort of the Phase 1 clinical trial and interim blinded data from the MAD portion of the study at the 2022 Alzheimer's Association ...
Successful completion of the second cohort establishes a clear pathway to selecting a dose for upcoming Phase 1b/2 clinical trials Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - ...
Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback